mario campone
mario campone
Institut De cancérologie de l'Ouest
Verified email at
Cited by
Cited by
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
CE Geyer, J Forster, D Lindquist, S Chan, CG Romieu, T Pienkowski, ...
New England journal of medicine 355 (26), 2733-2743, 2006
Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer
J Baselga, M Campone, M Piccart, HA Burris III, HS Rugo, T Sahmoud, ...
New England Journal of Medicine 366 (6), 520-529, 2012
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
SM Swain, J Baselga, SB Kim, J Ro, V Semiglazov, M Campone, ...
New England journal of medicine 372 (8), 724-734, 2015
Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
F André, E Ciruelos, G Rubovszky, M Campone, S Loibl, HS Rugo, ...
New England Journal of Medicine 380 (20), 1929-1940, 2019
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ...
New England journal of medicine 375 (18), 1738-1748, 2016
MONARCH 3: abemaciclib as initial therapy for advanced breast cancer
MP Goetz, M Toi, M Campone, J Sohn, S Paluch-Shimon, J Huober, ...
Journal of Clinical Oncology 35 (32), 3638-3646, 2017
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo …
SM Swain, SB Kim, J Cortés, J Ro, V Semiglazov, M Campone, E Ciruelos, ...
The lancet oncology 14 (6), 461-471, 2013
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated …
D Cameron, M Casey, M Press, D Lindquist, T Pienkowski, CG Romieu, ...
Breast cancer research and treatment 112, 533-543, 2008
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept …
C Le Tourneau, JP Delord, A Gonçalves, C Gavoille, C Dubot, N Isambert, ...
The lancet oncology 16 (13), 1324-1334, 2015
Lomustine and bevacizumab in progressive glioblastoma
W Wick, T Gorlia, M Bendszus, M Taphoorn, F Sahm, I Harting, ...
New England Journal of Medicine 377 (20), 1954-1963, 2017
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancer
J Baselga, V Semiglazov, P van Dam, A Manikhas, M Bellet, ...
Journal of Clinical Oncology 27 (16), 2630-2637, 2009
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
T Bachelot, G Romieu, M Campone, V Diéras, C Cropet, F Dalenc, ...
The lancet oncology 14 (1), 64-71, 2013
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial
H Roché, P Fumoleau, M Spielmann, JL Canon, T Delozier, D Serin, ...
Journal of Clinical Oncology 24 (36), 5664-5671, 2006
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced …
GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ...
Annals of Oncology 29 (7), 1541-1547, 2018
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
P Farmer, H Bonnefoi, P Anderle, D Cameron, P Wirapati, V Becette, ...
Nature medicine 15 (1), 68-74, 2009
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
ES Thomas, HL Gomez, RK Li, HC Chung, LE Fein, VF Chan, J Jassem, ...
Journal of Clinical Oncology 25 (33), 5210-5217, 2007
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
MJ van den Bent, AA Brandes, R Rampling, MCM Kouwenhoven, JM Kros, ...
Journal of Clinical Oncology 27 (8), 1268, 2009
Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE)
SRD Johnston, N Harbeck, R Hegg, M Toi, M Martin, ZM Shao, QY Zhang, ...
Journal of Clinical Oncology 38 (34), 3987-3998, 2020
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 …
SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ...
The Lancet Oncology 21 (4), 519-530, 2020
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
M Piccart, GN Hortobagyi, M Campone, KI Pritchard, F Lebrun, Y Ito, ...
Annals of oncology 25 (12), 2357-2362, 2014
The system can't perform the operation now. Try again later.
Articles 1–20